Antenatal Fetal Surveillance With Chronic Hypertension

Chronic hypertension is high blood pressure diagnosed before pregnancy, before 20 weeks’ gestation, or continuing beyond the postpartum period. During pregnancy, it increases the likelihood of pre-eclampsia, fetal growth restriction, placental abruption, medically indicated preterm birth and stillbirth. Antenatal monitoring therefore needs to assess both maternal wellbeing and the way the placenta is supporting the baby.

Antenatal fetal surveillance in chronic hypertension is not a single test performed at a fixed week. It is a planned sequence of blood pressure reviews, urine and blood tests, ultrasound examinations, Doppler studies and, later in pregnancy, cardiotocography where clinically indicated. The schedule depends on blood pressure control, medication, previous obstetric history, evidence of placental disease and any additional condition such as diabetes or kidney disease.

Australian care is usually shared between a general practitioner, midwife, obstetrician and, when required, a maternal-fetal medicine or neonatal service. The principles remain similar whether care is provided in a Sydney tertiary hospital, a Melbourne maternity unit or through a regional service in Queensland, Western Australia or the Northern Territory. Patients should receive an individual plan that explains what is being checked, when it will occur and which symptoms require urgent assessment.

How Chronic Hypertension Affects Pregnancy

Long-standing hypertension can alter the small blood vessels that supply the placenta. If placental development or blood flow is impaired, the fetus may receive less oxygen and nutrition, increasing the risk of fetal growth restriction. This is why serial growth scans are often more useful than relying on a single normal ultrasound early in pregnancy.

The condition also raises the risk of superimposed pre-eclampsia, in which new symptoms or abnormal laboratory findings develop on top of pre-existing hypertension. Warning signs include a persistent headache, visual disturbance, right upper abdominal or epigastric pain, sudden swelling, shortness of breath, nausea or a feeling of being acutely unwell. A normal home blood pressure reading does not exclude pre-eclampsia if symptoms are concerning.

At the first antenatal assessment, clinicians commonly establish a baseline blood pressure and review kidney function, liver enzymes, platelet count and urine protein. A medication review is essential because some antihypertensive drugs used outside pregnancy, including ACE inhibitors and angiotensin receptor blockers, are generally avoided during pregnancy. Labetalol, nifedipine or methyldopa may be considered, depending on the person’s medical history and treating team.

Building An Individual Monitoring Plan

A useful care plan begins with risk assessment. Important details include the cause and duration of hypertension, previous pre-eclampsia, prior fetal growth restriction or stillbirth, kidney disease, diabetes, autoimmune disease, multiple pregnancy and current blood pressure readings. Medication adherence, side effects and access to a reliable home monitor also influence the plan.

Low-dose aspirin is commonly recommended for people at increased risk of pre-eclampsia. In Australia, clinicians often prescribe 100–150 mg nightly from around 12–16 weeks until approximately 36 weeks, although the dose and timing must be determined by the treating practitioner. Aspirin is preventive; it does not replace blood pressure treatment, symptom assessment or fetal surveillance. It should be used only after checking allergies, bleeding risks and other medicines.

Home monitoring can make care more responsive, particularly between clinic visits. Patients should use a validated upper-arm device, rest for several minutes, keep the cuff at heart level and record readings with the date, time and symptoms. A single mildly elevated reading may need repeating, while severe hypertension or symptoms require prompt medical contact. Local maternity units may set different thresholds and instructions, so the written action plan should take priority.

Australian geography affects how this plan works in practice. A person living near Royal Prince Alfred Hospital or the Royal Women’s Hospital may have rapid access to specialist ultrasound, whereas someone in a remote community may need coordinated outreach, telehealth and planned travel to a regional centre. Medicare-funded antenatal services can reduce the cost of appointments, but transport, time away from work and accommodation near a tertiary hospital may still affect attendance.

Ultrasound And Placental Blood Flow Assessment

A dating scan and routine anatomical survey provide an early reference point, but they cannot reliably predict later placental dysfunction. Serial ultrasound is generally arranged in the second half of pregnancy to measure fetal biometry, estimate growth and assess amniotic fluid. The interval may be around three to four weeks, adjusted for the clinical situation and local protocol.

Estimated fetal weight is interpreted against gestational-age charts rather than as an isolated number. A fetus may be constitutionally small and healthy, or may show growth restriction through a falling growth trajectory, reduced abdominal circumference or abnormal fluid volume. Comparing measurements over time is therefore important. An unexpectedly large change in growth percentile should prompt review rather than automatic delivery.

Umbilical artery Doppler measures resistance to blood flow through the placenta and can help identify placental insufficiency. Middle cerebral artery Doppler, ductus venosus assessment and cerebroplacental ratio may be used by specialist services in selected cases, especially when fetal growth restriction is suspected. These tests are complementary; a reassuring Doppler result does not override maternal deterioration, reduced fetal movements or other abnormal findings.

The former congress resources from the Federation of Asian and Oceania Perinatal Societies provide useful historical context for clinicians interested in regional perinatal research and scientific practice through the FAOPS 2020 congress. Contemporary decisions, however, should follow current Australian guidance and the advice of the treating maternity team rather than an archived event program.

When Fetal Heart Rate Monitoring Helps

Cardiotocography, commonly called a CTG, records the fetal heart rate alongside uterine activity. It can assess short-term fetal wellbeing when there are reduced fetal movements, maternal symptoms, suspected growth restriction, abnormal Doppler findings or other concerns. In chronic hypertension without complications, routine daily or very early CTG may provide little benefit and can lead to unnecessary intervention.

The timing and frequency of CTG should reflect the whole clinical picture. A patient with stable blood pressure, normal growth, normal fluid and reassuring Dopplers may be monitored less intensively than someone with severe hypertension, declining growth or superimposed pre-eclampsia. CTG findings need interpretation by trained staff because fetal sleep cycles, medications and gestational age can affect the trace.

Reduced fetal movements require immediate assessment, not a wait for the next scheduled scan. Patients should follow the movement advice provided by their maternity service and contact the hospital if movements are less than usual or change noticeably. Australian hospitals commonly offer a maternity assessment unit or birth suite triage, although arrangements vary in rural and remote regions.

Pregnancy planning should include discussion of when delivery would be safer than continuing surveillance. The decision may be influenced by blood pressure severity, laboratory results, symptoms, fetal growth, Dopplers, CTG findings, gestational age and neonatal support available at the proposed hospital. A planned birth in Brisbane, Perth or Adelaide may involve transfer from a smaller service if very preterm birth is possible.

Coordinating Safe Follow-Up And Birth

The surveillance schedule should be documented in the antenatal record and shared with everyone involved in care. Under Australia’s Privacy Act 1988, health information must be handled appropriately, yet relevant information can be shared for clinical care with consent and within applicable health-service rules. Patients can ask how blood pressure readings, scan results and specialist letters will be communicated between providers.

Medication and blood pressure targets should be reviewed throughout pregnancy. Treatment decisions balance the risk of maternal stroke, heart failure and placental complications against possible effects of excessive blood pressure reduction. A person should not stop antihypertensive medication abruptly or change the dose based solely on a home reading without medical advice.

Local access to medicines can also matter. Common pregnancy-compatible antihypertensive drugs may be supplied through community pharmacies under the Pharmaceutical Benefits Scheme, but stock can vary, especially outside metropolitan areas. Keeping a current prescription, checking repeats before weekends or travel and taking a medication list to every appointment can prevent avoidable gaps in treatment.

The following summary shows how the main surveillance tools contribute to care:

Antenatal fetal surveillance in chronic hypertension works best when it is active, flexible and connected to a clear response plan. Attend scheduled reviews, take prescribed medicines as directed, record home blood pressure readings if advised and report warning symptoms promptly. Contact the maternity assessment service immediately for severe headache, visual changes, chest pain, breathing difficulty, significant abdominal pain, vaginal bleeding, a severe blood pressure reading or reduced fetal movements. Early assessment can help the clinical team protect both parent and baby.